表紙
市場調査レポート

薬物乱用 : パイプライン分析

Substance (Drug) Abuse - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229734
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
薬物乱用 : パイプライン分析 Substance (Drug) Abuse - Pipeline Review, H2 2015
出版日: 2015年10月30日 ページ情報: 英文 72 Pages
概要

薬物乱用は、気分を変える目的で、任意の物質を有害に使用するパターンとして定義されています。人は、さまざまな理由から、薬物、アルコール、タバコなどの物質を乱用します。一般的な兆候や症状は、不眠、中途覚醒、異常な怠惰、食欲低下または増加、食習慣の変化、低体温・手のひらの発汗、手の震え、赤・涙目、標準より大きい/小さい、不整脈、鼻水、空咳などが見られます。

当レポートでは、薬物乱用に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

薬物乱用の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Addex Therapeutics Ltd
  • Aelis Farma S.A.S.
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Foresee Pharmaceuticals, LLC
  • Grunenthal GmbH
  • Indivior Plc
  • InterveXion Therapeutics LLC
  • P2D Bioscience
  • Zynerba Pharmaceuticals, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 2E-2
  • ADX-71743
  • ADX-88178
  • AEF-0117
  • AT-076
  • AT-089
  • AT-212
  • CERC-501
  • Ch-mAb7F9
  • dronabinol
  • コカイン中毒用酵素
  • FP-004
  • コカイン中毒向けコカイン加水分解酵素活性化遺伝療法
  • RBP-8000
  • RO-656570
  • コカイン使用障害向けドーパミン D1, D2 および D3受容体拮抗小分子
  • 薬物乱用症およびアルコール依存症向けμオピオイド受容体拮抗小分子
  • カンナビノイド乱用および薬物依存症向けCB1受容体阻害小分子
  • 中枢神経系および薬物乱用向けドーパミン輸送体阻害小分子
  • 薬物乱用向けワクチン
  • メタンフェタミン乱用向けワクチン
  • VU-0463841

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7237IDB

Summary

Global Markets Direct's, 'Substance (Drug) Abuse - Pipeline Review, H2 2015', provides an overview of the Substance (Drug) Abuse's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Substance (Drug) Abuse
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Substance (Drug) Abuse and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Substance (Drug) Abuse products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Substance (Drug) Abuse pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Substance (Drug) Abuse
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Substance (Drug) Abuse pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Substance (Drug) Abuse Overview
  • Therapeutics Development
    • Pipeline Products for Substance (Drug) Abuse - Overview
    • Pipeline Products for Substance (Drug) Abuse - Comparative Analysis
  • Substance (Drug) Abuse - Therapeutics under Development by Companies
  • Substance (Drug) Abuse - Therapeutics under Investigation by Universities/Institutes
  • Substance (Drug) Abuse - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Substance (Drug) Abuse - Products under Development by Companies
  • Substance (Drug) Abuse - Products under Investigation by Universities/Institutes
  • Substance (Drug) Abuse - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aelis Farma S.A.S.
    • Astraea Therapeutics, LLC
    • Cerecor Inc.
    • Foresee Pharmaceuticals, LLC
    • Grunenthal GmbH
    • Indivior Plc
    • InterveXion Therapeutics LLC
    • P2D Bioscience
    • Zynerba Pharmaceuticals, Inc.
  • Substance (Drug) Abuse - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 2E-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEF-0117 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-076 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-089 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-212 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CERC-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ch-mAb7F9 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Enzyme for Cocaine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBP-8000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RO-656570 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Drug Abuse - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Methamphetamine Abuse - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VU-0463841 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Substance (Drug) Abuse - Recent Pipeline Updates
  • Substance (Drug) Abuse - Dormant Projects
  • Substance (Drug) Abuse - Product Development Milestones
    • Featured News & Press Releases
      • Jan 29, 2015: InterveXion Therapeutics, a UAMS Startup, Receives D14.5 Million to Develop Drug Therapies for Methamphetamine Users
      • Jan 05, 2015: InterveXion Therapeutics Receives D5 Million To Support Production Of The Anti-Methamphetamine Monoclonal Antibody
      • Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Substance (Drug) Abuse, H2 2015
  • Number of Products under Development for Substance (Drug) Abuse - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Substance (Drug) Abuse - Pipeline by Addex Therapeutics Ltd, H2 2015
  • Substance (Drug) Abuse - Pipeline by Aelis Farma S.A.S., H2 2015
  • Substance (Drug) Abuse - Pipeline by Astraea Therapeutics, LLC, H2 2015
  • Substance (Drug) Abuse - Pipeline by Cerecor Inc., H2 2015
  • Substance (Drug) Abuse - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
  • Substance (Drug) Abuse - Pipeline by Grunenthal GmbH, H2 2015
  • Substance (Drug) Abuse - Pipeline by Indivior Plc, H2 2015
  • Substance (Drug) Abuse - Pipeline by InterveXion Therapeutics LLC, H2 2015
  • Substance (Drug) Abuse - Pipeline by P2D Bioscience, H2 2015
  • Substance (Drug) Abuse - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Substance (Drug) Abuse Therapeutics - Recent Pipeline Updates, H2 2015
  • Substance (Drug) Abuse - Dormant Projects, H2 2015
  • Substance (Drug) Abuse - Dormant Projects (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Substance (Drug) Abuse, H2 2015
  • Number of Products under Development for Substance (Drug) Abuse - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top